GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: pVXc-486 | SPR720
Compound class:
Synthetic organic
Comment: Fobrepodacin (SPR720) is an orally administered prodrug that is being developed for the treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD) [3]. The active metabolite, SPR719, is a novel aminobenzimidazole antibacterial compound that is a dual Inhibitor of bacterial DNA gyrase and DNA topoisomerase 4 [1] .
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
| Is prodrug? | Yes |
| Active form | SPR719 |
IUPAC Name ![]() |
| 2-[5-[2-(ethylcarbamoylamino)-6-fluoro-7-[(2R)-oxolan-2-yl]-3H-benzimidazol-5-yl]pyrimidin-2-yl]propan-2-yl dihydrogen phosphate |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11650 | fobrepodacin |
Synonyms ![]() |
| pVXc-486 | SPR720 |
Database Links ![]() |
|
| Specialist databases | |
Antibiotic DB
|
SPR720 (phosphate prodrug of SPR719) |
| Other databases | |
| BindingDB Ligand | 50112815 |
| CAS Registry No. | 1384984-31-9 (source: Scifinder) |
| ChEMBL Ligand | CHEMBL2221212 |
| DrugBank Ligand | DB18409 |
| GtoPdb PubChem SID | 491299844 |
| PubChem CID | 68108988 |
| Search Google for chemical match using the InChIKey | COTQDURISRILOR-CQSZACIVSA-N |
| Search Google for chemicals with the same backbone | COTQDURISRILOR |
| Search PubMed clinical trials | fobrepodacin |
| Search PubMed titles | fobrepodacin |
| Search PubMed titles/abstracts | fobrepodacin |
| UniChem Compound Search for chemical match using the InChIKey | COTQDURISRILOR-CQSZACIVSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | COTQDURISRILOR-CQSZACIVSA-N |